image description

Tag: Dr. Keith Elkon

New Trial of Promising Lupus Treatment RSLV-132 Has Finished Enrolling Patients

July 30, 2019 Resolve Therapeutics announced that it has enrolled enough patients to conduct a Phase 2a study of a potential treatment for lupus, RSLV-132.  Grant support from the Lupus Research Alliance to Dr. Keith Elkon of the University of Washington supported the early work that led to the creation of the molecule RSLV-132. In lupus, […] Read More

LRA Grant Leads to New Drug Candidate RSLV-132

May 10, 2019 Grant support from the Lupus Research Alliance (then ALR) supported early work that led to a potential new drug, RSLV-132. In lupus, antibodies can target DNA’s chemical cousin RNA, which performs a variety of jobs in cells. When these antibodies encounter an RNA molecule, they attach to it, forming clusters that can […] Read More